Annual Incidence of Invasive Pneumococcal Disease and Incidence Rate Ratio for Persons With Selected Immunocompromising Conditions Relative to the Immunocompetent Population, 2010/2011, Toronto/Peel Region, Ontario
| . | . | Age Group (in Years) . | |||||
|---|---|---|---|---|---|---|---|
| Population . | All . | <15 y . | ≥15 y . | ||||
| N . | Incidencea . | IRR (95% CI) . | Incidencea . | IRR (95% CI) . | Incidencea . | IRR (95% CI) . | |
| Immunocompetent | 3 973 048 | 4.8 | 4.9 | 4.8 | |||
| Immunocompromised (all) | 112 439 | 56 | 12 (8.7–15) | 199 | 41 (18–91) | 53 | 11 (8.0–15) |
| Chronic renal failure requiring dialysisb | 2798 | 89 | 19 (5.3–65) | … | 107 | 22 (6.4–78) | |
| HIV infection | 19 274 | 56 | 11 (6.1–21) | 294 | 60 (3.7–986) | 52 | 11 (5.8–21) |
| Hematological malignancyc | 9038 | 266 | 55 (36–84) | 914 | 188 (67–531) | 233 | 48 (30–77) |
| Acute leukemia | 850 | 647 | 134 (58–313) | 1122 | 231 (77–694) | 371 | 77 (19–312) |
| Chronic leukemia | 1818 | 220 | 46 (17–124) | … | 220 | 46 (17–124) | |
| Lymphoma | 5184 | 106 | 22 (9.4–51) | 398 | 82 (5.0–1337) | 99 | 21 (8.4–50) |
| Multiple myeloma | 945 | 847 | 176 (87–358) | … | 847 | 176 (87–358) | |
| Solid organ/bone marrow transplant | 4377 | 217 | 45 (24–86) | 555 | 114 (22–585) | 195 | 41 (20–83) |
| Sickle cell disease | 1226 | 122 | 25 (5.1–127) | 248 | 51 (3.1–833) | 98 | 20 (2.8–145) |
| Systemic autoimmune diseased | 20 427 | 20 | 4.1 (1.5–11) | … | 18 | 3.7 (1.2–12) | |
| Immunosuppressive therapye | 55 300 | 19 | 3.9 (2.1–7.3) | … | 20 | 4.2 (2.2–7.8) | |
| . | . | Age Group (in Years) . | |||||
|---|---|---|---|---|---|---|---|
| Population . | All . | <15 y . | ≥15 y . | ||||
| N . | Incidencea . | IRR (95% CI) . | Incidencea . | IRR (95% CI) . | Incidencea . | IRR (95% CI) . | |
| Immunocompetent | 3 973 048 | 4.8 | 4.9 | 4.8 | |||
| Immunocompromised (all) | 112 439 | 56 | 12 (8.7–15) | 199 | 41 (18–91) | 53 | 11 (8.0–15) |
| Chronic renal failure requiring dialysisb | 2798 | 89 | 19 (5.3–65) | … | 107 | 22 (6.4–78) | |
| HIV infection | 19 274 | 56 | 11 (6.1–21) | 294 | 60 (3.7–986) | 52 | 11 (5.8–21) |
| Hematological malignancyc | 9038 | 266 | 55 (36–84) | 914 | 188 (67–531) | 233 | 48 (30–77) |
| Acute leukemia | 850 | 647 | 134 (58–313) | 1122 | 231 (77–694) | 371 | 77 (19–312) |
| Chronic leukemia | 1818 | 220 | 46 (17–124) | … | 220 | 46 (17–124) | |
| Lymphoma | 5184 | 106 | 22 (9.4–51) | 398 | 82 (5.0–1337) | 99 | 21 (8.4–50) |
| Multiple myeloma | 945 | 847 | 176 (87–358) | … | 847 | 176 (87–358) | |
| Solid organ/bone marrow transplant | 4377 | 217 | 45 (24–86) | 555 | 114 (22–585) | 195 | 41 (20–83) |
| Sickle cell disease | 1226 | 122 | 25 (5.1–127) | 248 | 51 (3.1–833) | 98 | 20 (2.8–145) |
| Systemic autoimmune diseased | 20 427 | 20 | 4.1 (1.5–11) | … | 18 | 3.7 (1.2–12) | |
| Immunosuppressive therapye | 55 300 | 19 | 3.9 (2.1–7.3) | … | 20 | 4.2 (2.2–7.8) | |
Abbreviations: CI, confidence interval; HIV, human immunodeficiency virus; IPD, invasive pneumococcal disease; IRR, incidence rate ratio.
a Cases of IPD per 100 000 persons/year.
b Population prevalence data were available for patients with renal failure requiring dialysis, but not for other patients with renal failure.
c Hematological malignancy includes acute leukemia, chronic leukemia, lymphoma, multiple myeloma, and other myelodysplastic and myeloproliferative disorders. There were no cases of chronic leukemia or myeloma in children.
d Includes systemic lupus erythematosus, systemic sclerosis, Sjögren syndrome, and polymyositis-dermatomyositis.
e Immunosuppressive therapy includes adult cases receiving immunosuppressive therapy with underlying COPD, asthma, inflammatory bowel disease or rheumatoid arthritis.
Annual Incidence of Invasive Pneumococcal Disease and Incidence Rate Ratio for Persons With Selected Immunocompromising Conditions Relative to the Immunocompetent Population, 2010/2011, Toronto/Peel Region, Ontario
| . | . | Age Group (in Years) . | |||||
|---|---|---|---|---|---|---|---|
| Population . | All . | <15 y . | ≥15 y . | ||||
| N . | Incidencea . | IRR (95% CI) . | Incidencea . | IRR (95% CI) . | Incidencea . | IRR (95% CI) . | |
| Immunocompetent | 3 973 048 | 4.8 | 4.9 | 4.8 | |||
| Immunocompromised (all) | 112 439 | 56 | 12 (8.7–15) | 199 | 41 (18–91) | 53 | 11 (8.0–15) |
| Chronic renal failure requiring dialysisb | 2798 | 89 | 19 (5.3–65) | … | 107 | 22 (6.4–78) | |
| HIV infection | 19 274 | 56 | 11 (6.1–21) | 294 | 60 (3.7–986) | 52 | 11 (5.8–21) |
| Hematological malignancyc | 9038 | 266 | 55 (36–84) | 914 | 188 (67–531) | 233 | 48 (30–77) |
| Acute leukemia | 850 | 647 | 134 (58–313) | 1122 | 231 (77–694) | 371 | 77 (19–312) |
| Chronic leukemia | 1818 | 220 | 46 (17–124) | … | 220 | 46 (17–124) | |
| Lymphoma | 5184 | 106 | 22 (9.4–51) | 398 | 82 (5.0–1337) | 99 | 21 (8.4–50) |
| Multiple myeloma | 945 | 847 | 176 (87–358) | … | 847 | 176 (87–358) | |
| Solid organ/bone marrow transplant | 4377 | 217 | 45 (24–86) | 555 | 114 (22–585) | 195 | 41 (20–83) |
| Sickle cell disease | 1226 | 122 | 25 (5.1–127) | 248 | 51 (3.1–833) | 98 | 20 (2.8–145) |
| Systemic autoimmune diseased | 20 427 | 20 | 4.1 (1.5–11) | … | 18 | 3.7 (1.2–12) | |
| Immunosuppressive therapye | 55 300 | 19 | 3.9 (2.1–7.3) | … | 20 | 4.2 (2.2–7.8) | |
| . | . | Age Group (in Years) . | |||||
|---|---|---|---|---|---|---|---|
| Population . | All . | <15 y . | ≥15 y . | ||||
| N . | Incidencea . | IRR (95% CI) . | Incidencea . | IRR (95% CI) . | Incidencea . | IRR (95% CI) . | |
| Immunocompetent | 3 973 048 | 4.8 | 4.9 | 4.8 | |||
| Immunocompromised (all) | 112 439 | 56 | 12 (8.7–15) | 199 | 41 (18–91) | 53 | 11 (8.0–15) |
| Chronic renal failure requiring dialysisb | 2798 | 89 | 19 (5.3–65) | … | 107 | 22 (6.4–78) | |
| HIV infection | 19 274 | 56 | 11 (6.1–21) | 294 | 60 (3.7–986) | 52 | 11 (5.8–21) |
| Hematological malignancyc | 9038 | 266 | 55 (36–84) | 914 | 188 (67–531) | 233 | 48 (30–77) |
| Acute leukemia | 850 | 647 | 134 (58–313) | 1122 | 231 (77–694) | 371 | 77 (19–312) |
| Chronic leukemia | 1818 | 220 | 46 (17–124) | … | 220 | 46 (17–124) | |
| Lymphoma | 5184 | 106 | 22 (9.4–51) | 398 | 82 (5.0–1337) | 99 | 21 (8.4–50) |
| Multiple myeloma | 945 | 847 | 176 (87–358) | … | 847 | 176 (87–358) | |
| Solid organ/bone marrow transplant | 4377 | 217 | 45 (24–86) | 555 | 114 (22–585) | 195 | 41 (20–83) |
| Sickle cell disease | 1226 | 122 | 25 (5.1–127) | 248 | 51 (3.1–833) | 98 | 20 (2.8–145) |
| Systemic autoimmune diseased | 20 427 | 20 | 4.1 (1.5–11) | … | 18 | 3.7 (1.2–12) | |
| Immunosuppressive therapye | 55 300 | 19 | 3.9 (2.1–7.3) | … | 20 | 4.2 (2.2–7.8) | |
Abbreviations: CI, confidence interval; HIV, human immunodeficiency virus; IPD, invasive pneumococcal disease; IRR, incidence rate ratio.
a Cases of IPD per 100 000 persons/year.
b Population prevalence data were available for patients with renal failure requiring dialysis, but not for other patients with renal failure.
c Hematological malignancy includes acute leukemia, chronic leukemia, lymphoma, multiple myeloma, and other myelodysplastic and myeloproliferative disorders. There were no cases of chronic leukemia or myeloma in children.
d Includes systemic lupus erythematosus, systemic sclerosis, Sjögren syndrome, and polymyositis-dermatomyositis.
e Immunosuppressive therapy includes adult cases receiving immunosuppressive therapy with underlying COPD, asthma, inflammatory bowel disease or rheumatoid arthritis.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
